宣泰医药
(688247)
| 流通市值:31.46亿 | | | 总市值:31.46亿 |
| 流通股本:4.53亿 | | | 总股本:4.53亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 282,579,550.28 | 191,160,204.92 | 94,546,671.06 | 446,568,888.08 |
| 营业总成本 | 265,321,926.33 | 173,790,467.08 | 82,432,049.12 | 394,329,144.83 |
| 其他经营收益 | | | | |
| 营业利润 | 35,835,358.18 | 29,949,498.06 | 14,924,782.56 | 55,318,824.23 |
| 利润总额 | 36,315,604.51 | 32,131,658.61 | 18,375,296.65 | 53,335,333.42 |
| 净利润 | 34,080,532.22 | 29,701,777.95 | 16,563,338.25 | 47,482,814.69 |
| 每股收益 | | | | |
| 其他综合收益 | -32,444.69 | -32,756.85 | -16,043.8 | -20,861.17 |
| 综合收益总额 | 34,048,087.53 | 29,669,021.1 | 16,547,294.45 | 47,461,953.52 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 992,957,484.57 | 977,919,135.72 | 955,309,544.35 | 934,873,260.06 |
| 非流动资产: | | | | |
| 非流动资产合计 | 497,998,517.52 | 497,064,549.14 | 498,760,415.03 | 503,226,123.37 |
| 资产总计 | 1,490,956,002.09 | 1,474,983,684.86 | 1,454,069,959.38 | 1,438,099,383.43 |
| 流动负债: | | | | |
| 流动负债合计 | 113,021,810.82 | 95,949,410.55 | 86,976,633.52 | 82,959,364.52 |
| 非流动负债: | | | | |
| 非流动负债合计 | 59,757,940.42 | 60,187,165.92 | 58,580,778.96 | 63,158,329.46 |
| 负债合计 | 172,779,751.24 | 156,136,576.47 | 145,557,412.48 | 146,117,693.98 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,318,176,250.85 | 1,318,847,108.39 | 1,308,512,546.9 | 1,291,981,689.45 |
| 股东权益合计 | 1,318,176,250.85 | 1,318,847,108.39 | 1,308,512,546.9 | 1,291,981,689.45 |
| 负债和股东权益合计 | 1,490,956,002.09 | 1,474,983,684.86 | 1,454,069,959.38 | 1,438,099,383.43 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 366,703,916.57 | 259,529,493.75 | 121,512,606.86 | 525,388,171.02 |
| 经营活动现金流出小计 | 278,546,732.72 | 174,481,612.14 | 81,335,248.17 | 430,062,312.71 |
| 经营活动产生的现金流量净额 | 88,157,183.85 | 85,047,881.61 | 40,177,358.69 | 95,325,858.31 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 744,402,040.04 | 406,857,527.71 | 166,248,724.65 | 1,971,636,920.89 |
| 投资活动现金流出小计 | 1,145,464,940.39 | 734,002,390.09 | 467,349,996.39 | 1,854,658,417.09 |
| 投资活动产生的现金流量净额 | -401,062,900.35 | -327,144,862.38 | -301,101,271.74 | 116,978,503.8 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | - | - |
| 筹资活动现金流出小计 | 6,302,069.42 | 6,284,854.38 | 16,840.8 | 27,906,438.83 |
| 筹资活动产生的现金流量净额 | -6,302,069.42 | -6,284,854.38 | -16,840.8 | -27,906,438.83 |
| 汇率变动对现金及现金等价物的影响 | -3,906,455.87 | -3,105,796.08 | -2,069,984.25 | -3,294,230.88 |
| 现金及现金等价物净增加额 | -323,114,241.79 | -251,487,631.23 | -263,010,738.1 | 181,103,692.4 |
| 期末现金及现金等价物余额 | 83,775,232.04 | 155,401,842.6 | 143,878,735.73 | 406,889,473.83 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -251,487,631.23 | - | 181,103,692.4 |